Treatment Patterns, Goals, and Decision-Making Criteria for Second- and Third-Line Therapies for Multiple Myeloma in Germany.

ABSTRACT:

Introduction

To document the decision-making criteria physicians use when selecting regimens for second- and third-line therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) in Germany.

Methods

Experienced multiple myeloma (MM) physicians extracted data from medical records from 30 June to 8 September 2023 for patients who initiated approved second- and third-line therapy for MM in 2021. Regimens, most important treatment goal, and key reasons for prescribing were reported in addition to patient characteristics. All data were summarised descriptively.

Results

MM physicians (33 hospital-based, 16 office-based) with a median of 17 years of treatment experience extracted data from a total of 268 patient records (second-line, n = 170; third-line, n 

SUBMITTER: Steinmetz HT 

PROVIDER: S-EPMC12313794 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature